WuXi hits the gas on coronavirus antibody development

Shanghai, China-based WuXi Biologics (HK: 2269) says it has increased efforts in enabling the development of multiple neutralizing antibodies for the current outbreak of a novel coronavirus (2019-nCoV), centered in Wuhan, China.

The firm says the antibodies under development, which are from global biotech companies, are “potent in neutralizing 2019-nCoV in preliminary studies.”

As the outbreak continues to gain strength, numerous countries have advised against unnecessary travel to China, while authorities in the country take more extensive actions to try to control the spread of the virus.